Status:
RECRUITING
Determination of Pancreatic Steatosis Prevalence and Correlation With High-risk Cyst Features
Lead Sponsor:
Chinese University of Hong Kong
Conditions:
Pancreatic Steatosis
Pancreatic Cyst
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Pancreatic cancer is the fifth leading cause of cancer mortality in Hong Kong and the seventh leading cause of cancer mortality worldwide. In 2020, approximately 496000 new cases of pancreatic cancers...
Detailed Description
Pancreatic cancer is the fifth leading cause of cancer mortality in Hong Kong and the seventh leading cause of cancer mortality worldwide. In 2020, approximately 496000 new cases of pancreatic cancers...
Eligibility Criteria
Inclusion
- Age 18 or older
- Patients with at least 1 pancreatic cystic lesion presumed to be IPMN or MCN based on CT, MRI or EUS features, with a cyst size ≥ 5mm; or healthy subjects.
- Patients who are able to provide written informed consent to participate in the study and comply with the study procedures.
Exclusion
- Unable to provide written informed consent
- Patients with metallic implants or other contraindications to MRI
- Patients with contraindications for endoscopy due to comorbidities
- Patients with known pancreatic cancer or prior pancreatic resection
- Patients with significant alcohol consumption, defined as alcohol intake of over 20 g daily (140 g weekly) for men and 10 g daily (70 g weekly) for women
Key Trial Info
Start Date :
April 6 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 30 2026
Estimated Enrollment :
236 Patients enrolled
Trial Details
Trial ID
NCT05334836
Start Date
April 6 2022
End Date
April 30 2026
Last Update
August 11 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Prince of Wales Hospital, The Chinese University of Hong Kong
Shatin, New Territories, Hong Kong